New data on Takeda’s dengue vaccine look promising, but with troubling exception
New data about the effectiveness of Takeda Pharmaceutical’s experimental dengue vaccine will likely raise more concerns among the many people hoping the vaccine will be an effective and safe tool with which to combat the massive global burden of dengue fever.
The company — which earlier this month published findings from a Phase 3 trial outlining responses to the vaccine after 12 months — presented 18-month data at the annual meeting of the American Society of Tropical Medicine and Hygiene in National Harbor, Md.
